RH5 is a blood-stage malaria vaccine candidate. Two versions of the RH5 vaccine developed by the University of Oxford are currently under clinical trials: RH5.1/Matrix-M – a protein in adjuvant vaccine and RH5.2/Matrix-M – a virus-like particle vaccine administered with matrix M adjuvant.